These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20377518)

  • 1. Recent advances in gastrointestinal pharmacology: from basic science to clinical practice.
    Mózsik G; Takeuchi K
    Curr Pharm Des; 2010; 16(10):1179. PubMed ID: 20377518
    [No Abstract]   [Full Text] [Related]  

  • 2. Forward peristalsis!--rapid progress in translational gastrointestinal pharmacology.
    Blackshaw LA; Aziz Q
    Curr Opin Pharmacol; 2011 Dec; 11(6):573-4. PubMed ID: 22000934
    [No Abstract]   [Full Text] [Related]  

  • 3. New pharmacologic therapies in gastrointestinal disease.
    Wallace JL; Ferraz JG
    Gastroenterol Clin North Am; 2010 Sep; 39(3):709-20. PubMed ID: 20951926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Enteropathy induced by nonsteroid anti-inflammatory drugs].
    Karateev AE; Nasonova VA
    Ter Arkh; 2004; 76(2):79-82. PubMed ID: 15106423
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).
    Lauritsen K; Laursen LS; Rask-Madsen J
    Clin Pharmacokinet; 1990 Aug; 19(2):94-125. PubMed ID: 2199130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological treatment of functional bowel disorders: any light at the end of the tunnel?
    Boeckxstaens GE
    Curr Opin Pharmacol; 2008 Dec; 8(6):669-70. PubMed ID: 18835367
    [No Abstract]   [Full Text] [Related]  

  • 7. Gastrointestinal neuropharmacology: identification of therapeutic targets.
    Furness JB; Sanger GJ
    Curr Opin Pharmacol; 2002 Dec; 2(6):609-11. PubMed ID: 12482721
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical pharmacology considerations in development of gastrohepatology products.
    Lee SC; Apparaju S; Kim I; Estes K; Jappar D; Bashaw ED
    Clin Pharmacol Ther; 2012 Sep; 92(3):281-3. PubMed ID: 22910484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.
    Camilleri M
    Clin Pharmacol Ther; 2012 Jan; 91(1):44-59. PubMed ID: 22071696
    [No Abstract]   [Full Text] [Related]  

  • 10. Advances in GI pharmacology and therapeutics.
    Scarpignato C; Di Mario F
    Dig Dis; 2006; 24(1-2):7-10. PubMed ID: 16699261
    [No Abstract]   [Full Text] [Related]  

  • 11. [Prokinetic drugs in gastroenterology].
    Galmiche JP; Bruley des Varannes S; Le Bodic L
    Gastroenterol Clin Biol; 1991; 15(2 ( Pt 3)):T7-10. PubMed ID: 2065903
    [No Abstract]   [Full Text] [Related]  

  • 12. Cannabinoids as gastrointestinal anti-inflammatory drugs.
    Fabisiak A; Fichna J
    Neurogastroenterol Motil; 2017 Mar; 29(3):. PubMed ID: 28239924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ion channels as targets for treatment of gastrointestinal motility disorders.
    Farrugia G
    Eur Rev Med Pharmacol Sci; 2008 Aug; 12 Suppl 1():135. PubMed ID: 18924455
    [No Abstract]   [Full Text] [Related]  

  • 14. Non-steroidal anti-inflammatory drugs and gastrointestinal disease: is there a better approach to NSAID use?
    Gabriel SE
    Ital J Gastroenterol Hepatol; 1998 Apr; 30(2):139-42. PubMed ID: 9675645
    [No Abstract]   [Full Text] [Related]  

  • 15. Upper gastrointestinal promotility drugs: not all uniform?
    Brun R; Kuo B
    Indian J Gastroenterol; 2009; 28(4):123-5. PubMed ID: 19937420
    [No Abstract]   [Full Text] [Related]  

  • 16. Appropriate use of gastrointestinal-protective agents in elderly needs clarification.
    Cavalieri TA
    J Am Osteopath Assoc; 1999 Jun; 99(6):301-2. PubMed ID: 10405515
    [No Abstract]   [Full Text] [Related]  

  • 17. Editorial overview: Gastrointestinal: New frontiers in therapeutics for GI diseases and disorders-from microRNAs to novel pharmaceutics, to low FODMAP diets and microbiome.
    Christofi FL; Bharucha AE
    Curr Opin Pharmacol; 2017 Dec; 37():iv-viii. PubMed ID: 29224799
    [No Abstract]   [Full Text] [Related]  

  • 18. Overview of 50 years' progress in upper gastrointestinal diseases.
    Yeomans ND
    J Gastroenterol Hepatol; 2009 Oct; 24 Suppl 3():S2-4. PubMed ID: 19799693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of new CCK2 receptor antagonists. A review of pharmacological studies. Part I: Development of potential therapeutic tools for gastrin-related gastrointestinal diseases.
    Revel L; Makovec F
    Methods Find Exp Clin Pharmacol; 1999 Jun; 21(5):375-83. PubMed ID: 10420394
    [No Abstract]   [Full Text] [Related]  

  • 20. [Can gastroduodenal lesions induced by non-steroidal anti-inflammatory agents be prevented?].
    Florent C; Florent M; Desaint B
    Rev Med Suisse Romande; 1992 Jun; 112(6):497-500. PubMed ID: 1631460
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.